Plain-English translation of NCT03981003 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Researchers are studying two proteins found in blood — neurofilament-light chain and GFAP — to see if they can be used as biomarkers that show how active your multiple sclerosis is and how disabled you might become. These blood markers could help doctors better understand your disease and track how well your treatment is working. This is not a medication trial; it's a research study looking at existing blood tests to improve MS care.
Currently, doctors use MRI scans and neurological exams to monitor MS, but these don't always give a complete picture of what's happening in the brain and nervous system. Blood markers could offer a simpler, faster way to detect disease activity and help doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would have blood drawn at your regular MS clinic visits at one of the participating French hospitals (Nîmes or Nantes). Depending on your disease status, you may be in a group tracking active MS (those with recent relapses or worsening) or stable MS. The study collects your blood samples over time alongside your regular medical care and tracks your disability scores and MRI results to see if the blood markers match what doctors observe clinically.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France